Streptozotocin in advanced small cell bronchogenic carcinoma: an ineffective nonmyelosuppressive agent.
作者信息
Bunn P A, Ihde D C, Cohen M H, Shackney S E, Minna J D
出版信息
Cancer Treat Rep. 1978 Mar;62(3):479-81.
PMID:148321
Abstract
Thirteen patients with advanced small cell bronchogenic carcinoma (SCBC) received at least three weekly cycles of iv streptozotocin (STZ). There were no objective responses. Four patients progressed by the third week of therapy and an additional eight by the fourth week. Toxicity was acceptable especially in view of the extensive prior therapy. STZ is unlikely to be of benefit in combination chemotherapy regiments for SCBC.
摘要
相似文献
1
Streptozotocin in advanced small cell bronchogenic carcinoma: an ineffective nonmyelosuppressive agent.
Cancer Treat Rep. 1978 Mar;62(3):479-81.
2
Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma.
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2105-6.
3
Streptozotocin: an inactive agent in small cell carcinoma.
Cancer Clin Trials. 1979 Spring;2(1):59-61.
4
5
Phase II studies on weekly cisplatinum plus epirubicin or etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
Chemioterapia. 1986 Aug;5(4):228-31.
6
Treatment of small cell bronchogenic carcinoma with VM-26.
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2011-3.
7
Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.
Cancer Treat Rep. 1981 Nov-Dec;65(11-12):947-54.
8
Combination chemotherapy in metastatic or recurrent non-small cell bronchogenic carcinoma. 5-year results.
Strahlentherapie. 1983 Dec;159(12):775-7.
9
10
Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II.
Cancer Treat Rep. 1981 Nov-Dec;65(11-12):965-72.
Zotero 插件